CEBPB and familial dilated cardiomyopathy: and sh‐C/EBPβ treatment enhanced the reduced MMP‐2 levels, whereas C/EBPβ overexpression increased MMP‐2 expression and activity by up‐regulating ACE2 expression, thus increasing the degradation of the ECM in mice with DCM.